2. Search Result
Search Result
Pathways Recommended: Anti-infection
Results for "

PA infection

" in MedChemExpress (MCE) Product Catalog:

15

Inhibitors & Agonists

1

Biochemical Assay Reagents

2

Peptides

1

Inhibitory Antibodies

2

Natural
Products

1

Oligonucleotides

Cat. No. Nombre del producto Target Áreas de investigación Chemical Structure
  • HY-128780B
    SPR206 acetate
    1 Publications Verification

    		 Bacterial Antibiotic Infection
    SPR206 acetate is a polymyxin analog with antibiotic activity against Gram-negative pathogens, including multidrug-resistant (MDR) variants. SPR206 acetate has an anti-bacterial infection effect by interacting with the bacterium’s outer membrane. The MIC values of SPR206 acetate against Pseudomonas aeruginosa Pa14 and Acinetobacter baumannii NCTC13301 are both 0.125 mg/L .
    SPR206 acetate
  • HY-P99649
    Gremubamab

    MEDI3902

    		 Bacterial Infection
    Gremubamab (MEDI3902) is a humanized IgG1 kappa anti-PcrV/Psl monoclonal antibody. Gremubamab binds to the PA PcrV protein and Psl exopolysaccharide. Gremubamab has the potential for the research of pseudomonas aeruginosa infections .
    Gremubamab
  • HY-N0842
    Bevirimat
    2 Publications Verification

    PA-457; MPC-4326; YK FH312

    		 Virus Protease Infection
    Bevirimat (PA-457, MPC-4326, YK FH312) is an inhibitor of HIV-1 viral particle maturation.Bevirimat specifically inhibits the final rate-limiting step in Gag processing, preventing the release of the mature capsid protein (CA) from its precursor (CA-SP1), resulting in the production of immature non-infectious viral particles. Bevirimat can be used in HIV-1 infection studies .
    Bevirimat
  • HY-W157376
    PAMAM Dendrimer G0.0 amine (20% in methanol)

    		Bacterial Antibiotic Drug Intermediate Infection Cancer
    PAMAM Dendrimer G0.0 amine is a pore-forming channel antagonist, including anthrax toxin protective antigen 63 (PA63, IC50 = 231 nM) and C. botulinum C2 toxin subunit (C2IIa, IC50 = 940 nM). At concentrations of 10 and 20 µM, PAMAM Dendrimer G0.0 amine reduces C2 toxin-induced death in HeLa cells. Additionally, PAMAM Dendrimer G0.0 amine is a chelator of nickel. In complexes with polysulfone membrane-bound chitosan, PAMAM Dendrimer G0.0 amine selectively captures and stores carbon dioxide (CO2) in a gas-feed system. PAMAM Dendrimer G0.0 amine has been used in the synthesis of PAMAM Dendrimer G0.5 Carboxylate (CAS 339334-01-9) and PAMAM Dendrimer G1.0 Amine (CAS 142986-44-5). PAMAM Dendrimer G0.0 amine can be used in research related to infections, cancer, and drug delivery systems .
    PAMAM Dendrimer G0.0 amine (20% in methanol)
  • HY-B0693A
    Ranitidine bismuth citrate

    		Histamine Receptor SARS-CoV Bacterial Infection Metabolic Disease Cancer
    Ranitidine bismuth citrate is a potent, selective and orally active histamine H2-receptor antagonist that inhibits gastric secretion. Ranitidine bismuth citrate antagonizes Histamine (HY-B1204)-induced increases of the guinea-pig isolated rat atrium and Histamine-induced relaxations of the rat isolated uterine horn, with pA2 values of 7.2 and 6.95, respectively. Ranitidine bismuth citrate has selectivity for SARS-CoV-2-infected cells. Ranitidine bismuth citrate also has anti-Helicobacter pylori infection. Ranitidine bismuth citrate inhibits breast tumor development and spread in mice .
    Ranitidine bismuth citrate
  • HY-P11091
    PA2-GNU7

    		Bacterial Infection
    PA2-GNU7 is an antimicrobial peptide (AMP). PA2-GNU7 exhibits potent antimicrobial activity with minimal inhibitory concentration (MIC) against P. aeruginosa, E. coli, S. typhimurium, S. aureus, and C. albicans are 2 μM, 1 μM, 2 μM, 2 μM, and 8 μM, respectively. PA2-GNU7 rapidly and selectively kills Pseudomonas aeruginosa without affecting other commensal bacteria. PA2-GNU7 significantly improves survival of mice infected with P. aeruginosa. PA2-GNU7 can be used for the research and development of therapeutic agents against MDR Pseudomonas aeruginosa infections .
    PA2-GNU7
  • HY-P11442
    Lytx-Pa2a

    Lycotoxin-PA2a; TBIU041425

    		 Bacterial Toll-like Receptor (TLR) Inflammation/Immunology
    Lytx-Pa2a (Lycotoxin-Pa2a) is a peptide inhibitor against bacterial membranes and TLR4 receptor. Lytx-Pa2a exerts antimicrobial effects via non-competitive disruption of outer/cytoplasmic membranes and suppression of LPS-induced TLR4/NF-κB signaling. Lytx-Pa2a is promising for research of bacterial infection and inflammation-related disease (e.g., sepsis) .
    Lytx-Pa2a
  • HY-157045
    ATP Synthesis-IN-1

    		ATP Synthase Infection
    ATP Synthesis-IN-1 (Compound 4), quinoline derivative, is a potent inhibitor of PA ATP synthesis activity. ATP Synthesis-IN-1 has PA ATP synthesis inhibition with IC50 value of 11.1μg/mL. ATP Synthesis-IN-1 also has antibacterial activity. ATP Synthesis-IN-1 can be used for the research of drug-resistant PA infection .
    ATP Synthesis-IN-1
  • HY-177775
    pro-N6pA

    		Nucleoside Antimetabolite/Analog Infection
    pro-N6pA is a cell-permeable pronucleotide probe. Pro-N6pA can be used to track AMPylated proteins. Pro-N6pA can also be used in bacterial infection research .
    pro-N6pA
  • HY-N0842R
    Bevirimat (Standard)

    PA-457 (Standard); MPC-4326 (Standard); YK FH312 (Standard)

    		 Reference Standards Virus Protease Infection
    Bevirimat (Standard) is the analytical standard of Bevirimat. This product is intended for research and analytical applications. Bevirimat (PA-457, MPC-4326, YK FH312) is an inhibitor of HIV-1 viral particle maturation.Bevirimat specifically inhibits the final rate-limiting step in Gag processing, preventing the release of the mature capsid protein (CA) from its precursor (CA-SP1), resulting in the production of immature non-infectious viral particles. Bevirimat can be used in HIV-1 infection studies[1][2][3][4].
    Bevirimat (Standard)
  • HY-173270
    Antibacterial synergist 3

    		Bacterial Infection
    Antibacterial synergist 3 is a dual-acting inhibitor of biofilm (IC50 of PAO1: 0.40 μM and IC50 of PA14: 1.45 μM). Antibacterial synergist 3 reduces virulence production by inhibiting the quorum sensing (QS) system and induces iron deficiency in P. aeruginosa PAO1. Antibacterial synergist 3 enhances the efficacy of Tobramycin (HY-B0441) and Ciprofloxacin (HY-B0356) in a mouse wound infection model. Antibacterial synergist 3 can be used for the research of P. aeruginosa infections .
    Antibacterial synergist 3
  • HY-178366
    PAC/NP-IN-1

    		Influenza Virus Infection
    PAC/NP-IN-1 (Compound 30) is a dual-target anti-influenza agent that specifically binds to nucleoprotein (NP) and the C-terminal domain of PA protein (PAc). PAC/NP-IN-1 inhibits influenza A virus A/WSN/33 (H1N1) (EC50 = 3.63 μM, IC50 = 3.08 μM). PAC/NP-IN-1 can be used for the study of influenza infection .
    PAC/NP-IN-1
  • HY-NP216
    PA-IIL

    LecB

    		 Integrin Endogenous Metabolite Bacterial Infection
    PA-IIL (LecB) is a lectin produced by Pseudomonas aeruginosa. PA-IIL binds to glycosylated β1-integrin, fucose-containing glycosphingolipids, fucosylated/mannosylated neutrophil glycoconjugates, and pre-formed neutrophil extracellular traps. PA-IIL disrupts host defenses: it creates favorable conditions for Pseudomonas aeruginosa infection and dissemination by modulating the bactericidal activity of neutrophils, impairing the trafficking and recruitment of immune cells, and compromising the repair capacity of epithelial barriers. PA-IIL can be used in studies related to Pseudomonas aeruginosa infection .
    PA-IIL
  • HY-180115
    Antibacterial agent 315

    		Bacterial MMP Infection
    LP07 is an antibacterial agent targeting Pseudomonas aeruginosa with MIC values for both wild-type and efflux pump-deficient P. aeruginosa PA14 of both 8 μg/mL. LP07 exerts its antibacterial effect by directly disrupting the structural integrity of the bacterial cell membrane. LP07 moderately inhibits MMP-17 and MMP-19, but has no significant inhibitory effect on other MMP subtypes. LP07 does not inhibit the activity of LpxC enzyme. LP07 can be used for research on Pseudomonas aeruginosa infections .
    Antibacterial agent 315
  • HY-180269
    Anti-Influenza agent 10

    		Influenza Virus DNA/RNA Synthesis Infection
    Anti-Influenza agent 10 (Compound 41) is an influenza A virus RNA-dependent RNA polymerase (RdRp) inhibitor. Anti-Influenza agent 10 exhibits potent antiviral activity against A/PR/8/34(H1N1) with an IC50 of 0.29μM and a KD of 4.11 μM. Anti-Influenza agent 10 can inhibit the assembly of the viral RdRp complex by disrupting the protein interaction between PA and PB1 subunits, thereby blocking the transcription and replication of the viral genome. Anti-Influenza agent 10 shows significant broad-spectrum effects on multiple influenza virus strains, such as H3N2, H3N8 and H9N2 with IC50 values of 3.96, 1.91 and 1.45 μM. Anti-Influenza agent 10 can be used for the research of influenza A Virus Infection .
    Anti-Influenza agent 10

Consulta en línea

Your information is safe with us. * Required Fields.

Saludo

  

Country or Region *

Nombre del solicitante *

 

Nombre de la Organizaciòn *

Department *

     

Direcciòn del E-mail *

 

Nombre del producto *

Cat. No.

  

Requested quantity *

Número de teléfono *

     

Observaciones

Consulta en línea

Inquiry Information

Nombre del producto:
Cat. No.:
Cantidad:
MCE Japan Authorized Agent: